X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with TTK HEALTHCARE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs TTK HEALTHCARE - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA TTK HEALTHCARE AUROBINDO PHARMA/
TTK HEALTHCARE
 
P/E (TTM) x 19.3 22.8 84.5% View Chart
P/BV x 4.8 7.7 63.2% View Chart
Dividend Yield % 0.3 0.4 84.9%  

Financials

 AUROBINDO PHARMA   TTK HEALTHCARE
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
TTK HEALTHCARE
Mar-14
AUROBINDO PHARMA/
TTK HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs895663 134.9%   
Low Rs622399 155.9%   
Sales per share (Unadj.) Rs254.6535.6 47.5%  
Earnings per share (Unadj.) Rs39.315.9 246.3%  
Cash flow per share (Unadj.) Rs46.620.0 232.6%  
Dividends per share (Unadj.) Rs2.504.00 62.5%  
Dividend yield (eoy) %0.30.8 43.8%  
Book value per share (Unadj.) Rs160.0137.6 116.2%  
Shares outstanding (eoy) m585.887.77 7,540.3%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.01.0 300.4%   
Avg P/E ratio x19.333.3 58.0%  
P/CF ratio (eoy) x16.326.5 61.4%  
Price / Book Value ratio x4.73.9 122.8%  
Dividend payout %6.425.1 25.4%   
Avg Mkt Cap Rs m444,3904,127 10,766.8%   
No. of employees `00014.01.7 818.6%   
Total wages/salary Rs m17,678607 2,914.2%   
Avg. sales/employee Rs Th10,667.82,436.7 437.8%   
Avg. wages/employee Rs Th1,264.3355.2 356.0%   
Avg. net profit/employee Rs Th1,645.872.5 2,268.8%   
INCOME DATA
Net Sales Rs m149,1574,162 3,584.0%  
Other income Rs m1,15961 1,893.6%   
Total revenues Rs m150,3164,223 3,559.5%   
Gross profit Rs m34,343197 17,424.0%  
Depreciation Rs m4,27632 13,489.9%   
Interest Rs m66730 2,231.4%   
Profit before tax Rs m30,558197 15,535.4%   
Minority Interest Rs m500-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7,59773 10,434.8%   
Profit after tax Rs m23,012124 18,573.0%  
Gross profit margin %23.04.7 486.2%  
Effective tax rate %24.937.0 67.2%   
Net profit margin %15.43.0 518.2%  
BALANCE SHEET DATA
Current assets Rs m92,0621,629 5,652.5%   
Current liabilities Rs m66,2231,058 6,260.5%   
Net working cap to sales %17.313.7 126.3%  
Current ratio x1.41.5 90.3%  
Inventory Days Days10630 355.9%  
Debtors Days Days6834 201.5%  
Net fixed assets Rs m62,919556 11,310.2%   
Share capital Rs m58678 754.1%   
"Free" reserves Rs m93,133878 10,603.8%   
Net worth Rs m93,7191,069 8,764.5%   
Long term debt Rs m1,814159 1,143.0%   
Total assets Rs m162,4942,399 6,772.3%  
Interest coverage x46.87.6 617.5%   
Debt to equity ratio x00.1 13.0%  
Sales to assets ratio x0.91.7 52.9%   
Return on assets %14.66.4 227.3%  
Return on equity %24.611.6 211.9%  
Return on capital %32.718.5 177.4%  
Exports to sales %00.8 0.0%   
Imports to sales %01.4 0.0%   
Exports (fob) Rs mNA33 0.0%   
Imports (cif) Rs mNA58 0.0%   
Fx inflow Rs m75,83833 230,509.7%   
Fx outflow Rs m30,22463 47,830.8%   
Net fx Rs m45,613-30 -150,589.0%   
CASH FLOW
From Operations Rs m32,786127 25,897.2%  
From Investments Rs m-17,870-146 12,240.0%  
From Financial Activity Rs m-19,15322 -87,454.8%  
Net Cashflow Rs m-4,2393 -169,548.0%  

Share Holding

Indian Promoters % 54.1 65.4 82.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 3.7 214.9%  
FIIs % 27.7 5.2 532.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 25.8 39.5%  
Shareholders   69,601 12,723 547.0%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   BIOCON LTD  CADILA HEALTHCARE  VENUS REMEDIES  PANACEA BIOTECH  WOCKHARDT LTD.  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 290 Points; Realty and PSU Stocks Witness Selling(Closing)

After opening the day on a negative note, share markets in India continued their downtrend throughout the day and ended in red.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 12.0% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 12.0% YoY). Sales on the other hand came in at Rs 43 bn (up 15.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

TTK HEALTHCARE Announces Quarterly Results (1QFY19); Net Profit Down 276.0% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, TTK HEALTHCARE has posted a net profit of Rs 79 m (down 276.0% YoY). Sales on the other hand came in at Rs 2 bn (up 38.1% YoY). Read on for a complete analysis of TTK HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

As the Rupee Takes a Record Plunge, These Pharma Stocks Gain the Most(Sector Info)

Sep 5, 2018

Most pharma stocks were trading with gains amid rupee's fresh fall. Does that mean pharma stocks are back in vogue?

Why Arun Jaitley's Demonetisation Defence Doesn't Add Up(Vivek Kaul's Diary)

Sep 5, 2018

The tax collected has gone up a little but the question is at what cost.

The Cream of Small Cap Stocks(Profit Hunter)

Sep 5, 2018

Akin to skimming the cream off milk, one needs to learn to skim the cream off small cap stocks.

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Sep 18, 2018 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS